Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сартаны в кардиологической практике: новые возможности в терапии сердечно-сосудистой патологии
Сартаны в кардиологической практике: новые возможности в терапии сердечно-сосудистой патологии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ключевые слова: Артераильная гипертония, антагонисты рецептора ангиотензина II
________________________________________________
Полный текст
Список литературы
1. Полосьянц О.Б. Сартаны в кардиологической практике. Рос. мед. журн., 2008.
2. Чазова И.Е., Ратова Л.Г. Двойная блокада ренин-ангиотензиновой системы:новые возможности в лечении сердечно-сосудистых заболеваний. Consilium Medicum.
3. Стуров Н.В. Применение лозартана в кардиологической практике. Трудн. пациент. 2007; 11.
4. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2 (3): 581–90.
5. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 14 (116): 700–5.
6. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23 (4): 891–8.
7. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 66 (4): 1714–5.
8. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14 (17): 1879–86.
9. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369–79.
10. Кобалава Ж.Д., Толкачева В.В. Мочевая кислота – ключевое связующее звено кардиоренального континуума? Часть 1. Клин. фармакол. тер. 2003; 12 (3): 15–9.
11. Wurzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19 (10): 1855–60.
12. Ramsay LE, Williams B, Johnston GD et al. Guidelines for management of hypertension: report of the working party of the British Hypertension Society. J Hum Hypert 1999; 13: 569–92.
13. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
14. Agha A, Bashir K, Anwar E. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. Nepal Med Coll J 2007; 9 (2): 79–83.
15. Lozano JV, Llisterri JL, Aznar J et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 85–9.
16. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
17. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18 (5): 1540–6.
18. Carswell CI, Goa KL. Losartan in diabetic nephropathy. Drugs 2003; 63 (4): 407–14.
19. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 15 (349): 747–52.
20. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 6 (355): 1582–7.
21. Shahinfar S, Lyle PA, Zhang Z et al. Losartan: lessons learned from the RENAAL study. Expert Opin Pharmacother 2006; 7 (5): 623–30.
22. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журн. сердечн. недостат. 2007; 8: 2.
23. Sosa-Canache B, Hernandez-Hernandez R, Armas-Padilla MC et al. Effect of losartan therapy on endothelial function in hypertensive patients. Am J Ther 2007; 14 (2): 166–71.
24. Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25 (4): 785–91.
25. Диагностика и лечение артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2008, 7 (Прил. 2): 6.
2. Чазова И.Е., Ратова Л.Г. Двойная блокада ренин-ангиотензиновой системы:новые возможности в лечении сердечно-сосудистых заболеваний. Consilium Medicum.
3. Стуров Н.В. Применение лозартана в кардиологической практике. Трудн. пациент. 2007; 11.
4. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2 (3): 581–90.
5. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 14 (116): 700–5.
6. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23 (4): 891–8.
7. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 66 (4): 1714–5.
8. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14 (17): 1879–86.
9. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369–79.
10. Кобалава Ж.Д., Толкачева В.В. Мочевая кислота – ключевое связующее звено кардиоренального континуума? Часть 1. Клин. фармакол. тер. 2003; 12 (3): 15–9.
11. Wurzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19 (10): 1855–60.
12. Ramsay LE, Williams B, Johnston GD et al. Guidelines for management of hypertension: report of the working party of the British Hypertension Society. J Hum Hypert 1999; 13: 569–92.
13. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
14. Agha A, Bashir K, Anwar E. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. Nepal Med Coll J 2007; 9 (2): 79–83.
15. Lozano JV, Llisterri JL, Aznar J et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 85–9.
16. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
17. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18 (5): 1540–6.
18. Carswell CI, Goa KL. Losartan in diabetic nephropathy. Drugs 2003; 63 (4): 407–14.
19. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 15 (349): 747–52.
20. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 6 (355): 1582–7.
21. Shahinfar S, Lyle PA, Zhang Z et al. Losartan: lessons learned from the RENAAL study. Expert Opin Pharmacother 2006; 7 (5): 623–30.
22. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журн. сердечн. недостат. 2007; 8: 2.
23. Sosa-Canache B, Hernandez-Hernandez R, Armas-Padilla MC et al. Effect of losartan therapy on endothelial function in hypertensive patients. Am J Ther 2007; 14 (2): 166–71.
24. Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25 (4): 785–91.
25. Диагностика и лечение артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2008, 7 (Прил. 2): 6.
Авторы
О.Г. Смоленская
Кафедра внутренних болезней №1 ГОУ ВПО УГМА Росздрава
FSC VPO UGMA Roszdrav
Кафедра внутренних болезней №1 ГОУ ВПО УГМА Росздрава
________________________________________________
FSC VPO UGMA Roszdrav
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.